Volume | 4,060,589 |
|
|||||
News | - | ||||||
Day High | 2.265 | Low High |
|||||
Day Low | 2.12 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Esperion Therapeutics Inc | ESPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.25 | 2.12 | 2.265 | 2.25 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
11,344 | 4,060,589 | US$ 2.16 | US$ 8,778,135 | - | 0.70 - 3.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
13:41:28 | 5 | US$ 2.127 | USD |
Esperion Therapeutics (ESPR) Options Flow Summary
Esperion Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
394.16M | 185.05M | - | 116.33M | -209.25M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Esperion Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ESPR Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.60 | 2.63 | 2.12 | 2.37 | 7,107,368 | -0.47 | -18.08% |
1 Month | 2.01 | 2.63 | 1.88 | 2.27 | 8,383,015 | 0.12 | 5.97% |
3 Months | 2.52 | 3.40 | 1.71 | 2.40 | 7,591,455 | -0.39 | -15.48% |
6 Months | 1.24 | 3.40 | 1.1601 | 2.35 | 6,848,907 | 0.89 | 71.77% |
1 Year | 1.63 | 3.40 | 0.70 | 1.98 | 5,096,363 | 0.50 | 30.67% |
3 Years | 21.00 | 26.77 | 0.70 | 3.52 | 2,838,612 | -18.87 | -89.86% |
5 Years | 51.37 | 79.989 | 0.70 | 8.08 | 1,951,557 | -49.24 | -95.85% |
Esperion Therapeutics Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. |